Taysha Gene Therapies, Inc. Income Statement
TSHA / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Taysha Gene Therapies, Inc. reported $10M in revenue and $109M in net loss for FY2025. Revenue has grown at a 57.5% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $15.5M | $2.5M | $2.5M | - | - |
| SG&A Expense | $33.9M | $30.0M | $37.4M | $41.3M | $41.3M | $11.1M |
| R&D Expense | $86.4M | $56.8M | $91.2M | $131.9M | $131.9M | $31.9M |
| Operating Income | -$110.5M | -$72.4M | -$162.4M | -$173.3M | -$173.3M | -$43.0M |
| Interest Expense | - | - | $3.8M | $1.4M | $1.4M | $28.0K |
| Income Tax | $0 | $0 | $0 | $0 | - | $0 |
| Net Income | -$109.0M | -$111.6M | -$166.0M | -$174.5M | -$174.5M | -$60.0M |
| EPS (Basic) | -$0.36 | -$0.96 | -$3.78 | -$4.64 | -$4.64 | - |
| EPS (Diluted) | -$0.36 | -$0.96 | -$3.78 | -$4.64 | -$4.64 | - |
| Shares Outstanding | 204.9M | 187.0M | 63.2M | 38.5M | 37.7M | 17.7M |
| Operating Margin | -1130.7% | -468.8% | -6492.7% | -6925.1% | - | - |
| Profit Margin | -1115.3% | -722.1% | -6635.3% | -6975.3% | - | - |